Johnson & Johnson (JNJ)
| Market Cap | 542.42B +51.9% |
| Revenue (ttm) | 96.36B +5.1% |
| Net Income | 21.04B +71.1% |
| EPS | 8.64 +71.3% |
| Shares Out | 2.41B |
| PE Ratio | 26.09 |
| Forward PE | 19.09 |
| Dividend | $5.36 (2.32%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 13,899,597 |
| Open | 231.23 |
| Previous Close | 230.80 |
| Day's Range | 224.59 - 231.50 |
| 52-Week Range | 149.04 - 251.71 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 252.96 (+12.26%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $252.96, which is an increase of 12.26% from the latest price.
News
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypica...
Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study
Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival and overall survival ...
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second lin...
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today th...
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaq...
Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Management projects surpassing $100 billion in 2026 revenue, with accelerating growth driven by a robust pipeline in innovative medicines and MedTech. Oncology, cardiovascular, and surgical robotics are key growth drivers, while AI and drug-device synergies enhance R&D productivity. Portfolio reshaping and early-stage M&A support long-term ambitions.
Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launc...
Johnson & Johnson says nipocalimab approved in China
Johnson & Johnson's nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday.
Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026
The EP market is experiencing rapid growth, driven by AFib procedures, innovation, and global expansion, with strong leadership and a robust pipeline of new catheters and mapping technologies. The neurovascular franchise focuses on high-impact stroke solutions and less invasive treatments for chronic conditions.
Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, today announced that Johnson & Johnson has secured naming rig...
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managin...
Johnson & Johnson upgraded to Outperform from Market Perform at Leerink
Leerink analyst David Risinger upgraded Johnson & Johnson to Outperform from Market Perform with a $265 price target
Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026
The conference highlighted a robust R&D pipeline focused on oncology, immunology, and neuroscience, with recent advances in oral therapies and combination treatments. Regulatory and policy discussions centered on FDA leadership changes, evolving drug pricing models, and the growing impact of China on biopharma innovation.
Johnson & Johnson announces global launch of Shockwave C2 Aero catheter
Johnson & Johnson announced the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the t...
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participa...
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstract...
This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J
Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission Campaign draws on expertise...
CVS to drop J&J's Stelara from its main formularies
CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars over Johnson & Johnson's psoriasis drug Stelara in its most common drug lists starting July 1.
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24...
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to ...
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the se...